Cargando…

Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461136/ https://www.ncbi.nlm.nih.gov/pubmed/26082656 http://dx.doi.org/10.2147/CCID.S88448

Ejemplares similares

Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
por: Menon, Roshni, et al.
Publicado: (2015)

Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017)

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab
por: Caballero, Armando, et al.
Publicado: (2020)

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
por: Saavedra, Danay, et al.
Publicado: (2020)

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
por: Singh, Vinay
Publicado: (2016)

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2017)

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla, Leelavathy, et al.
Publicado: (2019)

Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2018)

Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis
por: Kura, Mahendra M., et al.
Publicado: (2022)

[Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth
por: Xuan, Zi-Xue, et al.
Publicado: (2023)

Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis
por: Kierkus, Jaroslaw, et al.
Publicado: (2020)

Literature Overview of the Relation Between Psoriasis and Alzheimer [Corrigendum]
Publicado: (2023)

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
por: Parthasaradhi, Anchala, et al.
Publicado: (2017)

Corrigendum to: Are there ‘two sides’ to attacks on healthcare? Evidence from Palestine
Publicado: (2021)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Publicado: (2022)

Corrigendum to: Maintenance Immunosuppression Is Associated With Better Outcome in the 2017/2018 Influenza Epidemic
por: Stahl, Klaus, et al.
Publicado: (2020)

Corrigendum to “Handedness Side and Magnetization Transfer Ratio in the Primary Sensorimotor Cortex Central Sulcus”
por: Mascalchi, Mario, et al.
Publicado: (2020)

Corrigendum to “Approximations to the Voice of a Cochlear Implant: Explorations With Single-Sided Deaf Listeners”
Publicado: (2021)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Publicado: (2015)

Overexpression of Lin28a Aggravates Psoriasis-Like Phenotype by Regulating the Proliferation and Differentiation of Keratinocytes [Corrigendum]
Publicado: (2021)

Corrigendum to “The Story of CD4(+)CD28(−) T Cells Revisited: Solved or Still Ongoing?”
por: Maly, Kathrin, et al.
Publicado: (2015)

Specific Binding of Novel SPION-Based System Bearing Anti-N-Cadherin Antibodies to Prostate Tumor Cells [Corrigendum]
Publicado: (2022)

Corrigendum to “Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease”
por: Zhang, Guangzhi, et al.
Publicado: (2020)

Corrigendum to: Development of bispecific antibodies in China: overview and prospects
por: Zhang, Jing, et al.
Publicado: (2022)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

[Corrigendum] Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti‑apoptotic proteins
por: Račkauskas, Rokas, et al.
Publicado: (2023)

Corrigendum to: Anti-Inflammatory Efficacy of Human-Derived Streptococcus salivarius on Periodontopathogen-Induced Inflammation
por: Baek, Dong-Heon, et al.
Publicado: (2023)

Corrigendum: Comparative Analysis of Human Epidermal and Peripheral Blood γδ T Cell Cytokine Profiles
por: Kim, Kwangmi, et al.
Publicado: (2014)

Corrigendum to “Superoxide Anion Production and Bioenergetic Profile in Young and Elderly Human Primary Myoblasts”
por: Marrone, Mariangela, et al.
Publicado: (2021)

Corrigendum to “Influence of the Thermal Treatment to Address a Better Osseointegration of Ti6Al4V Dental Implants: Histological and Histomorphometrical Study in a Rabbit Model”
por: Scarano, Antonio, et al.
Publicado: (2018)

Corrigendum to “Anti-Interleukin-16-Neutralizing Antibody Attenuates Cardiac Inflammation and Protects against Cardiac Injury in Doxorubicin-Treated Mice”
por: Zhang, Jianwei, et al.
Publicado: (2022)

Corrigendum: ICTV Virus Taxonomy Profile: Ophioviridae
por: García, María Laura, et al.
Publicado: (2018)

Corrigendum: ICTV Virus Taxonomy Profile: Chrysoviridae
por: Ghabrial, Said A., et al.
Publicado: (2018)

Corrigendum to “Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis” [Neoplasia 19.9 (2017) 716-733]
por: Tati, Swetha, et al.
Publicado: (2017)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]
Publicado: (2019)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Corrigendum to ‘Regenerative technologies to bed side: Evolving the regulatory’ [J Orthop Translat 9 (2017) 1–7]
por: Sakai, Daisuke, et al.
Publicado: (2018)

Corrigendum: A generalized quantitative antibody homeostasis model: antigen saturation, natural antibodies and a quantitative antibody network
por: Prechl, József
Publicado: (2017)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4jeq6hnjr6go3lvf8m78o9o5ub